Skip to main content

Advertisement

SpringerLink
Log in

Serum irisin is a novel biomarker for bladder cancer detection

  • Urology - Original Paper
  • Published:
International Urology and Nephrology Aims and scope Submit manuscript

Abstract

Background

This study intended to investigate irisin levels in bladder cancer patients and healthy controls.

Objective

Our aim was to evaluate if serum irisin could be used as a diagnostic tool in bladder cancer and further, if it could differentiate muscle-invasive and non-muscle-invasive bladder cancer patients.

Methods

In this study, 90 primary bladder cancer patients in addition to 30 age-matched healthy individuals for the control group were prospectively included. Bladder cancer patients were divided into two subgroups as non-muscle-invasive (60 patients) and muscle-invasive (30 patients). Blood samples were obtained before the diagnosis of the disease. Serum irisin levels were measured using ELISA. Demographic data as well as tumor grade and stage were noted.

Results

Mean serum irisin level was significantly lower in the bladder cancer patients compared to the control group (4.53 ± 2.55 vs. 16.5 ± 5.67, p < 0.001). Also, serum irisin level was statistically lower in the muscle-invasive bladder cancer group compared to the non-muscle-invasive counterparts (3.19 ± 1.47 vs. 5.18 ± 2.73, p < 0.001). Serum irisin could differentiate bladder cancer patients from healthy individuals with a sensitivity of 86.2% and a specificity of 89.7% at a cut-off value of 8.689 (AUC = 0.859). Moreover, to discriminate between NMIBC and MIBC, the sensitivity was 75% and the specificity was 73.7% at a cut-off value of 3.97 (AUC = 0.732).

Conclusion

Our results showed that serum irisin levels can be used for the diagnosis of bladder cancer. Also, it can help distinguish high-grade and stage tumor.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

Data availability

Data availability is limited due to institutional data protection law and confidentiality of patient data.

References

  1. Bostrom P, Wu J, Jedrychowski MP, Korde A, Ye L, Lo JC et al (2012) A PGC1-alpha-dependent myokine that drives brown-fat-like development of white fat and thermogenesis. Nature 481(7382):463–468 (PubMed PMID: 22237023. Pubmed Central PMCID: PMC3522098. Epub 2012/01/13)

    Article  Google Scholar 

  2. Pedersen BK, Akerstrom TC, Nielsen AR, Fischer CP (2007) Role of myokines in exercise and metabolism. J Appl Physiol 103(3):1093–1098 (PubMed PMID: 17347387. Epub 2007/03/10)

    Article  CAS  Google Scholar 

  3. Moreno-Navarrete JM, Ortega F, Serrano M, Guerra E, Pardo G, Tinahones F et al (2013) Irisin is expressed and produced by human muscle and adipose tissue in association with obesity and insulin resistance. J Clin Endocrinol Metab 98(4):769–778 (PubMed PMID: 23436919. Epub 2013/02/26)

    Article  Google Scholar 

  4. Aydin S, Kuloglu T, Aydin S, Kalayci M, Yilmaz M, Cakmak T et al (2014) A comprehensive immunohistochemical examination of the distribution of the fat-burning protein irisin in biological tissues. Peptides 61:130–136 (PubMed PMID: 25261800. Epub 2014/09/28)

    Article  CAS  Google Scholar 

  5. Shi G, Tang N, Qiu J, Zhang D, Huang F, Cheng Y et al (2017) Irisin stimulates cell proliferation and invasion by targeting the PI3K/AKT pathway in human hepatocellular carcinoma. Biochem Biophys Res Commun 493(1):585–591 (PubMed PMID: 28867187. Epub 2017/09/05)

    Article  CAS  Google Scholar 

  6. Aydin S, Kuloglu T, Ozercan MR, Albayrak S, Aydin S, Bakal U et al (2016) Irisin immunohistochemistry in gastrointestinal system cancers. Biotech Histochem 91(4):242–250 (PubMed PMID: 26963139. Epub 2016/03/11)

    Article  CAS  Google Scholar 

  7. Provatopoulou X, Georgiou GP, Kalogera E, Kalles V, Matiatou MA, Papapanagiotou I et al (2015) Serum irisin levels are lower in patients with breast cancer: association with disease diagnosis and tumor characteristics. BMC Cancer 15:898 (PubMed PMID: 26560078. Pubmed Central PMCID: PMC4642638. Epub 2015/11/13)

    Article  Google Scholar 

  8. Siegel R, Ma J, Zou Z, Jemal A (2014) Cancer statistics, 2014. CA Cancer J Clin 64(1):9–29 (PubMed PMID: 24399786. Epub 2014/01/09)

    Article  Google Scholar 

  9. Burger M, Catto JW, Dalbagni G, Grossman HB, Herr H, Karakiewicz P et al (2013) Epidemiology and risk factors of urothelial bladder cancer. Eur Urol 63(2):234–241 (PubMed PMID: 22877502. Epub 2012/08/11)

    Article  Google Scholar 

  10. Freedman ND, Silverman DT, Hollenbeck AR, Schatzkin A, Abnet CC (2011) Association between smoking and risk of bladder cancer among men and women. JAMA 306(7):737–745 (PubMed PMID: 21846855. Pubmed Central PMCID: PMC3441175. Epub 2011/08/19)

    Article  CAS  Google Scholar 

  11. Keimling M, Behrens G, Schmid D, Jochem C, Leitzmann MF (2014) The association between physical activity and bladder cancer: systematic review and meta-analysis. Br J Cancer 110(7):1862–1870 (PubMed PMID: 24594995. Pubmed Central PMCID: PMC3974090. Epub 2014/03/07)

    Article  CAS  Google Scholar 

  12. Maalouf GE, El Khoury D (2019) Exercise-induced irisin, the fat browning myokine, as a potential anticancer agent. J Obes 2019:6561726 (PubMed PMID: 31065382. Pubmed Central PMCID: PMC6466922. Epub 2019/05/09)

    Article  Google Scholar 

  13. Zhang D, Tan X, Tang N, Huang F, Chen Z, Shi G (2020) Review of research on the role of irisin in tumors. Onco Targets Ther 13:4423–4430 (PubMed PMID: 32547073. Pubmed Central PMCID: PMC7245464. Epub 2020/06/18)

    Article  CAS  Google Scholar 

  14. Us Altay D, Keha EE, Ozer Yaman S, Ince I, Alver A, Erdogan B et al (2016) Investigation of the expression of irisin and some cachectic factors in mice with experimentally induced gastric cancer. QJM 109(12):785–790 (PubMed PMID: 27256459. Epub 2016/06/04)

    Article  Google Scholar 

  15. Liu J, Song N, Huang Y, Chen Y (2018) Irisin inhibits pancreatic cancer cell growth via the AMPK-mTOR pathway. Sci Rep 8(1):15247 (PubMed PMID: 30323244. Pubmed Central PMCID: PMC6189061. Epub 2018/10/17)

    Article  Google Scholar 

  16. Shaw RJ, Cantley LC (2006) Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature 441(7092):424–430 (PubMed PMID: 16724053. Epub 2006/05/26)

    Article  CAS  Google Scholar 

  17. Wysocki PJ (2009) mTOR in renal cell cancer: modulator of tumor biology and therapeutic target. Expert Rev Mol Diagn 9(3):231–241 (PubMed PMID: 19379082. Epub 2009/04/22)

    Article  CAS  Google Scholar 

  18. Esawy MM, Abdel-Samd KM (2020) The diagnostic and prognostic roles of serum irisin in bladder cancer. Curr Probl Cancer 44(4):100529 (PubMed PMID: 32139156. Epub 2020/03/07)

    Article  Google Scholar 

  19. Avritscher EB, Cooksley CD, Grossman HB, Sabichi AL, Hamblin L, Dinney CP et al (2006) Clinical model of lifetime cost of treating bladder cancer and associated complications. Urology 68(3):549–553 (PubMed PMID: 16979735. Epub 2006/09/19)

    Article  Google Scholar 

Download references

Funding

Not applicable.

Author information

Authors and Affiliations

  1. Department of Urology, Faculty of Medicine, Van Yuzuncu Yıl University, 65080, Van, Turkey

    Kerem Taken, Rahmi Aslan & Recep Eryilmaz

  2. Department of Medical Biochemistry, Faculty of Medicine, Van Yuzuncu Yıl University, 65080, Van, Turkey

    Hamit Hakan Alp & Zübeyir Huyut

  3. Department of Urology, İstanbul Faculty of Medicine, İstanbul University, İstanbul Tıp Fakültesi Cerrahi Monoblok, Fatih, 34093, İstanbul, Turkey

    Muhammet İrfan Dönmez

Authors
  1. Kerem Taken
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Rahmi Aslan
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Recep Eryilmaz
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Hamit Hakan Alp
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Zübeyir Huyut
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Muhammet İrfan Dönmez
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

KT: conceptualization; data curation; formal analysis; investigation; methodology; project administration; resources; software; supervision; roles/writing—original draft. RA: conceptualization; data curation; formal analysis; investigation; methodology; project administration; resources; roles/writing—original draft. RE: conceptualization; data curation; formal analysis. HHA: data curation; investigation; resources. ZH: data curation; investigation; resources. MİD: roles/writing—original draft; writing—review and editing. All authors had access to the study data, also have read and agreed to the published version of the manuscript.

Corresponding author

Correspondence to Muhammet İrfan Dönmez.

Ethics declarations

Conflict of interest

The authors (KT, RA, RE, HHA, ZH, MİD) declare no competing interest.

Ethical approval

Van Yuzuncu Yıl University IRB number: 19/12/2018-13.

Informed consent

Informed consent was obtained from all participants.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Taken, K., Aslan, R., Eryilmaz, R. et al. Serum irisin is a novel biomarker for bladder cancer detection. Int Urol Nephrol 54, 55–61 (2022). https://doi.org/10.1007/s11255-021-03074-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11255-021-03074-4

Keywords

Search

Navigation